2026-08-16T14:18:08Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/134032023-08-27T12:10:57Zcom_20.500.14352_14col_20.500.14352_15

Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation Yadav, Monika Guzmán Aránguez, Ana Isabel Pérez de Lara, María Jesús Singh, Mandeep Singh, Joga Kaur, Indu Pal 617.7-007.681:615.457 615.457:617.732 Glaucoma Nanomedicine Sustained delivery Fluorescence Cytotoxicity Ocular Oftalmología Anatomía ocular Bioquímica (Farmacia) 3201.09 Oftalmología Received 24 October 2018; Received in revised form 7 May 2019; Accepted 7 May 2019; Available online 10 May 2019 Primary treatment for glaucoma relies on chronic instillation (daily) of intraocular pressure (IOP) lowering eye drops. Present study tends to develop and assess a novel sustained release bimatoprost loaded nanovesicular (BMT-NV) - thermosensitive in-situ gelling implant (BMT-NV- GEL-IM), for subconjunctival delivery. BMT-NVs developed using novel composition and method of preparation, (IPA/700/DEL/2014) and industrially viable methodology were characterized and evaluated comprehensively for ocular suitability. Their incorporation into an in-situ gelling formula was safe (in vitro and in vivo) and stable upon sterilization. Autoclavability was an important consideration, as a preservative-free, single-use BMT-NV- GEL-IM will avoid side- effects associated with repetitive application of drops containing preservatives like benzalkonium chloride (BAK). An extended in vitro release of BMT (80.23%) was observed for 10 days while the IOP lowering effect extended over 2 months with single subconjunctival injection of BMT-NV-GEL-IM in rats. No clinical signs of irritation, inflammation, or infection were observed in any injected eye, throughout the study, as also confirmed by histology. Furthermore, single administration of BMT-NV-GEL as topical drop lowered the IOP over 5 days. Presence of significant diffuse fluorescence in confocal microscopy of internal eye tissues post-in vivo application, as subconjunctival implant, even after 2 month and eye drops upto1 week provide direct evidence of successful sustained delivery. We thus provide an improved modality for antiglaucoma medication in patients who are challenged to adhere to a regimen of daily eye drops. UGC-RFMS fellowship Unidad Docente de Bioquímica y Biología Molecular Fac. de Óptica y Optometría TRUE pub 2023-06-17T13:24:40Z 2023-06-17T13:24:40Z 2019-05-10 journal article https://hdl.handle.net/20.500.14352/13403 0928-4931 10.1016/j.msec.2019.05.015 eng Atribución-NoComercial-SinDerivadas 3.0 España https://creativecommons.org/licenses/by-nc-nd/3.0/es/ open access application/pdf Elsevier